Arthur Ryan sells 100 Regeneron (REGN) shares in planned trades

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Regeneron Pharmaceuticals director Arthur F. Ryan sold 100 shares of common stock in a series of open-market transactions on March 2, 2026 under a Rule 10b5-1(c) trading plan adopted on October 31, 2025. The shares were sold at volume-weighted average prices ranging from $777.08 to $789.37 per share. After these sales, Ryan directly owned 17,703 Regeneron shares.

Insider Trade Summary

Net Seller: 100 shares ($78,550)

Net Sell 13 txns

Insider RYAN ARTHUR F

Role Director

Sold 100 shs ($79K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7	$777.46	$5K
Sale	Common Stock	2	$778.30	$2K
Sale	Common Stock	5	$779.69	$4K
Sale	Common Stock	3	$780.69	$2K
Sale	Common Stock	2	$781.21	$2K
Sale	Common Stock	2	$782.62	$2K
Sale	Common Stock	10	$783.62	$8K
Sale	Common Stock	9	$784.48	$7K
Sale	Common Stock	11	$785.48	$9K
Sale	Common Stock	7	$786.61	$6K
Sale	Common Stock	2	$787.34	$2K
Sale	Common Stock	20	$788.96	$16K
Sale	Common Stock	20	$789.28	$16K

Holdings After Transaction: Common Stock — 17,796 shares (Direct)

Footnotes (1)

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $777.08 to $777.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $778.27 to $778.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 5 shares of Company stock on March 2, 2026 at prices ranging from $779.36 to $779.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 3 shares of Company stock on March 2, 2026 at prices ranging from $780.13 to $780.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $781.00 to $781.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $782.25 to $782.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 10 shares of Company stock on March 2, 2026 at prices ranging from $783.25 to $783.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 9 shares of Company stock on March 2, 2026 at prices ranging from $784.02 to $784.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 11 shares of Company stock on March 2, 2026 at prices ranging from $785.02 to $785.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $786.12 to $786.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $787.02 to $787.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. Represents volume-weighted average price of sales of 20 shares of Company stock on March 2, 2026 at prices ranging from $789.27 to $789.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RYAN ARTHUR F

(Last)

(First)

(Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN

10591

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		S⁽¹⁾		7	D	$777.46⁽²⁾	17,796	D
Common Stock	03/02/2026		S⁽¹⁾		2	D	$778.3⁽³⁾	17,794	D
Common Stock	03/02/2026		S⁽¹⁾		5	D	$779.69⁽⁴⁾	17,789	D
Common Stock	03/02/2026		S⁽¹⁾		3	D	$780.69⁽⁵⁾	17,786	D
Common Stock	03/02/2026		S⁽¹⁾		2	D	$781.21⁽⁶⁾	17,784	D
Common Stock	03/02/2026		S⁽¹⁾		2	D	$782.62⁽⁷⁾	17,782	D
Common Stock	03/02/2026		S⁽¹⁾		10	D	$783.62⁽⁸⁾	17,772	D
Common Stock	03/02/2026		S⁽¹⁾		9	D	$784.48⁽⁹⁾	17,763	D
Common Stock	03/02/2026		S⁽¹⁾		11	D	$785.48⁽¹⁰⁾	17,752	D
Common Stock	03/02/2026		S⁽¹⁾		7	D	$786.61⁽¹¹⁾	17,745	D
Common Stock	03/02/2026		S⁽¹⁾		2	D	$787.34⁽¹²⁾	17,743	D
Common Stock	03/02/2026		S⁽¹⁾		20	D	$788.96	17,723	D
Common Stock	03/02/2026		S⁽¹⁾		20	D	$789.28⁽¹³⁾	17,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.

2. Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $777.08 to $777.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

3. Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $778.27 to $778.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

4. Represents volume-weighted average price of sales of 5 shares of Company stock on March 2, 2026 at prices ranging from $779.36 to $779.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

5. Represents volume-weighted average price of sales of 3 shares of Company stock on March 2, 2026 at prices ranging from $780.13 to $780.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

6. Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $781.00 to $781.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

7. Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $782.25 to $782.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

8. Represents volume-weighted average price of sales of 10 shares of Company stock on March 2, 2026 at prices ranging from $783.25 to $783.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

9. Represents volume-weighted average price of sales of 9 shares of Company stock on March 2, 2026 at prices ranging from $784.02 to $784.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

10. Represents volume-weighted average price of sales of 11 shares of Company stock on March 2, 2026 at prices ranging from $785.02 to $785.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

11. Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $786.12 to $786.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

12. Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $787.02 to $787.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

13. Represents volume-weighted average price of sales of 20 shares of Company stock on March 2, 2026 at prices ranging from $789.27 to $789.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price.

	/s/ Arthur F. Ryan	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did REGN director Arthur F. Ryan report?

Arthur F. Ryan reported selling 100 shares of Regeneron common stock in open-market transactions. The trades occurred on March 2, 2026, and were executed under a pre-arranged Rule 10b5-1(c) plan adopted on October 31, 2025, according to the Form 4 filing.

How many Regeneron (REGN) shares did Arthur F. Ryan sell and at what prices?

Arthur F. Ryan sold 100 Regeneron shares in multiple small trades. The Form 4 states volume-weighted average sale prices ranged from about $777.08 to $789.37 per share, reflecting executions across several price points during March 2, 2026 trading.

Does Arthur F. Ryan still hold Regeneron (REGN) shares after this Form 4?

Yes. After the reported sales, Arthur F. Ryan directly owned 17,703 Regeneron common shares. The Form 4 lists updated direct ownership following the last transaction on March 2, 2026, showing his remaining stake after disposing of 100 shares.

Was the REGN insider sale by Arthur F. Ryan under a Rule 10b5-1 plan?

Yes. A footnote explains the disposition was made under a plan intended to comply with Rule 10b5-1(c), adopted on October 31, 2025. Such plans pre-schedule trades, helping insiders sell shares according to pre-set instructions.

What type of transactions did Arthur F. Ryan execute in Regeneron stock?

The Form 4 describes the trades as open-market sales of Regeneron common stock. Each line item is coded “S” for sale, with volume-weighted average prices and small share amounts reported across multiple executions on March 2, 2026.

How many individual sale transactions did REGN director Arthur F. Ryan report?

The Form 4 itemizes 13 separate non-derivative sale transactions in Regeneron common stock. Each entry shows a small number of shares sold, the specific volume-weighted average price, and the updated direct share balance after each sale on March 2, 2026.